{‘She has zero expertise’: this American healthcare establishment braces for Dr. Høeg's role at the FDA.

As America proceeds with historic adjustments to its vaccine schedules, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots in the global health crisis and has zeroed in on possible deaths following COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Schedule

Agency leaders were set to unveil sweeping changes to the childhood vaccine schedule recently, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for benefit. The planned update has been pushed back until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s CDER, the fifth individual to head the office this year.

A Shift at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for halting certain pediatric shot schedules in the US to become more in line with the Danish model, a nation with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – typically the purview of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, oversight or leadership, which has been standard for previous directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for running the CDER, stated Jonathan Howard. “She’s never run a scientific study. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Past directors of CBER would “understand laws and regulations and the science of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an vast workload at the agency, Woodcock stated.

“The public just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be managed,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the role, which manages over 5,000 personnel. “It is a massive management job, if you do it right,” the former official concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Høeg’s credentials and whether this assignment represents greater collaboration among regulatory chiefs on immunizations, a representative stated that the “concerns rely on incorrect presumptions”.

“Her experience matches the duties of her role,” the official said, noting the period Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's controversial fast-track approval initiative, a controversial expedited drug-approval program that allegedly troubled her preceding directors. “How are these medications being picked for this fast-track system? Who takes the choices?” Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer regulations of pharmaceuticals, aside from vaccines.”

Public History on Immunizations

Regarding vaccines, Høeg has a more documented, if problematic, track record, critics have noted. She released a research paper using non-validated crowd-sourced reports to assess the rate of myocarditis following COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming administration featured altering guidelines for new vaccines and ending “unnecessary” immunizations, she stated post-election on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a highly misleading, untruthful fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|